Which ports are nearest for export?

The nearest ports are Tianjin Xingang, Qingdao, and Shanghai.

What international commercial terms are accepted?

Accepted Incoterms include FOB, CFR, CIF, CIP, and EXW.

Is the production line GMP approved?

Yes, the production lines are GMP approved and feature full automation control.

Pharmaceutical API Raw Material Azithromycin

Name: Pharmaceutical API Raw Material Azithromycin
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 765186502

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$10.00-500.00

2,000 kg

Sample price:US$1.00/piece.Request sample

Product profile

Customization

Available

Production Line

GMP Approved

Transport Package

Drum

Model NO.

Pharmaceutical Grade

Specification

25kg/drum

Trademark

SHIMEN

Origin

Hebei

Production Capacity

10000ton

Key features

GMP Approved Production: Manufactured on GMP approved production lines ensuring international advanced quality standards.

White Crystalline Powder: Characterized as white or almost white crystalline powder, odorless and bitter in taste.

Respiratory Infection Treatment: Mainly used for respiratory tract and skin soft tissue infections caused by susceptible bacteria.

Chlamydia Treatment: Effective for treating Chlamydia transmitted diseases as indicated in the product profile.

Molecular Formula C38H72N2O12: Precise molecular composition with a molecular weight of 749.00 for pharmaceutical accuracy.

70-Year Business History: Shijiazhuang No. 4 Pharmaceutical Co., Ltd. boasts a seventy-year history in the pharmaceutical industry.

Full Automation Control: Production and logistics processes feature full automation and information control systems.

Global Export Reach: Products exported to over 80 countries across Asia, Americas, Europe, Oceania, and Africa.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤9.82hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.